Literature DB >> 16140584

High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

Yangbing Zhao1, Zhili Zheng, Cyrille J Cohen, Luca Gattinoni, Douglas C Palmer, Nicholas P Restifo, Steven A Rosenberg, Richard A Morgan.   

Abstract

The use of nonviral gene transfer methods in primary lymphocytes has been hampered by low gene transfer efficiency and high transfection-related toxicity. In this report, high gene transfection efficiency with low transfection-related toxicity was achieved by electroporation using in vitro-transcribed mRNA. Using these methods, >90% transgene expression with >80% viable cells was observed in stimulated primary human and murine T lymphocytes transfected with GFP or mCD62L. Electroporation of unstimulated human PBMCs or murine splenocytes with GFP RNA yielded 95 and 56% GFP+ cells, respectively. Electroporation of mRNA for NY-ESO-1, MART-1, and p53 antigen-specific TCRs into human T lymphocytes redirected these lymphocytes to recognize melanoma cell lines in an MHC-restricted manner. The onset of gene expression was rapid (within 30 min) and durable (up to 7 days postelectroporation) using both GFP and TCR-mediated recognition of target cells. There was no adverse effect observed on the T lymphocytes subjected to RNA electroporation evaluated by cell growth rate, annexin-V staining of apoptotic cells, BrdU incorporation, tumor antigen-specific recognition or antigen-specific TCR affinity. The results of this study indicate that mRNA electroporation provides a powerful tool to introduce genes into both human and murine primary T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140584      PMCID: PMC1473967          DOI: 10.1016/j.ymthe.2005.07.688

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

1.  IL-7 is critical for homeostatic proliferation and survival of naive T cells.

Authors:  J T Tan; E Dudl; E LeRoy; R Murray; J Sprent; K I Weinberg; C D Surh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.

Authors:  V F Van Tendeloo; P Ponsaerts; F Lardon; G Nijs; M Lenjou; C Van Broeckhoven; D R Van Bockstaele; Z N Berneman
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery.

Authors:  V F Van Tendeloo; R Willems; P Ponsaerts; M Lenjou; G Nijs; M Vanhove; P Muylaert; P Van Cauwelaert; C Van Broeckhoven; D R Van Bockstaele; Z N Berneman
Journal:  Gene Ther       Date:  2000-08       Impact factor: 5.250

4.  High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes.

Authors:  T Rudoll; K Phillips; S W Lee; S Hull; O Gaspar; N Sucgang; E Gilboa; C Smith
Journal:  Gene Ther       Date:  1996-08       Impact factor: 5.250

5.  Intracellular delivery of lipopolysaccharide during DNA transfection activates a lipid A-dependent cell death response that can be prevented by polymyxin B.

Authors:  M Cotten; M Saltik
Journal:  Hum Gene Ther       Date:  1997-03-20       Impact factor: 5.695

6.  Lymphocyte apoptosis: induction by gene transfer techniques.

Authors:  O Ebert; S Finke; A Salahi; M Herrmann; B Trojaneck; P Lefterova; E Wagner; R Kircheis; D Huhn; F Schriever; I G Schmidt-Wolf
Journal:  Gene Ther       Date:  1997-04       Impact factor: 5.250

7.  Neutrophil rolling altered by inhibition of L-selectin shedding in vitro.

Authors:  B Walcheck; J Kahn; J M Fisher; B B Wang; R S Fisk; D G Payan; C Feehan; R Betageri; K Darlak; A F Spatola; T K Kishimoto
Journal:  Nature       Date:  1996-04-25       Impact factor: 49.962

8.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

9.  Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors.

Authors:  E Costello; M Munoz; E Buetti; P R Meylan; H Diggelmann; M Thali
Journal:  Gene Ther       Date:  2000-04       Impact factor: 5.250

10.  CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients.

Authors:  Adrian F Ochsenbein; Stanley R Riddell; Michele Brown; Lawrence Corey; Gabriela M Baerlocher; Peter M Lansdorp; Philip D Greenberg
Journal:  J Exp Med       Date:  2004-12-06       Impact factor: 14.307

View more
  118 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

3.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 4.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

5.  Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Authors:  Yangbing Zhao; Zhili Zheng; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

6.  Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.

Authors:  Miwako Narita; Nozomi Tochiki; Anri Saitoh; Norihiro Watanabe; Masami Kaji; Noriyuki Satoh; Akie Yamahira; Takeshi Nakamura; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2008-12-05       Impact factor: 3.064

7.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Authors:  Cyrille J Cohen; Jared J Gartner; Miryam Horovitz-Fried; Katerina Shamalov; Kasia Trebska-McGowan; Valery V Bliskovsky; Maria R Parkhurst; Chen Ankri; Todd D Prickett; Jessica S Crystal; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

8.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Authors:  Samudra K Dissanayake; Purevdorj B Olkhanud; Michael P O'Connell; Arnell Carter; Amanda D French; Tura C Camilli; Chineye D Emeche; Kyle J Hewitt; Devin T Rosenthal; Poloko D Leotlela; Michael S Wade; Sherry W Yang; Larry Brant; Brian J Nickoloff; Jane L Messina; Arya Biragyn; Keith S Hoek; Dennis D Taub; Dan L Longo; Vernon K Sondak; Stephen M Hewitt; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

10.  Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).

Authors:  Sung Hee Yoon; Jin Myung Lee; Sun-Je Woo; Min-Ji Park; Jung-Sun Park; Hye-Sung Kim; Mi-Young Park; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  J Clin Immunol       Date:  2009-06-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.